Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Osteopore Ltd. ( (AU:OSX) ) just unveiled an announcement.
Osteopore Limited has drawn a further A$250,000 sub-tranche (ST18) from Tranche 1 of its 4.0% redeemable convertible notes facility with Advance Opportunities Fund and Advance Opportunities Fund I, taking total subscriptions under Tranche 1 to A$4.5 million out of a planned A$5 million. The funds raised under the up-to-A$20 million multi-tranche notes program are earmarked for use in the ordinary course of business and to support future developments, projects and investments as opportunities arise, bolstering Osteopore’s capital position as it seeks to expand its regenerative implant operations and pursue growth initiatives.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Limited is a Singapore-founded, Australian-Singaporean regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The company commercialises patented scaffold products that stimulate natural bone healing across multiple clinical segments, using a proprietary 3D-printing process and naturally dissolving polymers to guide bone-forming cells and reduce post-surgery complications associated with permanent implants.
Average Trading Volume: 1,429,536
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.11M
Find detailed analytics on OSX stock on TipRanks’ Stock Analysis page.